PDCD1 and lung cancer: To the best of our knowledge, this is the first study to demonstrate the feasibility of patient stratification for evaluating the anti-PD-1 therapy response based on the TOX expression level in TI T cells for multiple types of cancer (melanoma and lung cancer).